Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the sale, the chief financial officer now owns 215,340 shares of the company’s stock, valued at approximately $2,597,000.40. This trade represents a 4.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Mineralys Therapeutics Trading Down 0.3 %

NASDAQ:MLYS traded down $0.04 during trading hours on Tuesday, reaching $13.88. 440,438 shares of the company traded hands, compared to its average volume of 413,614. The business’s 50-day moving average price is $12.36 and its two-hundred day moving average price is $12.34. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The stock has a market capitalization of $871.46 million, a P/E ratio of -3.81 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Mineralys Therapeutics in the 4th quarter worth $48,000. ProShare Advisors LLC purchased a new position in Mineralys Therapeutics in the 4th quarter worth about $128,000. China Universal Asset Management Co. Ltd. lifted its stake in Mineralys Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after acquiring an additional 989 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Mineralys Therapeutics by 9,602.2% during the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock valued at $140,000 after acquiring an additional 8,738 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Mineralys Therapeutics in the fourth quarter worth approximately $145,000. Institutional investors own 84.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. The Goldman Sachs Group decreased their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, February 13th. HC Wainwright raised their target price on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, April 2nd. Finally, Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.